Sugi Predict

Sugi Predict / Compounds / SCHEMBL280500

SCHEMBL280500

SCHEMBL280500

CCCCOC[C@H]1OC(OC)[C@H](OCCCC)[C@@H]1OCCCC

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SSTR1 P30872 4/20 0.52
▸ SSTR2 P30874 4/20 0.52
▸ SSTR4 P31391 4/20 0.52
▸ SSTR3 P32745 4/20 0.52
▸ SSTR5 P35346 4/20 0.52
▸ TNF P01375 2/20 0.46
▸ GJB2 P29033 4/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ FGF1 P05230 3/20 0.33
▸ FGF2 P09038 3/20 0.33
▸ VEGFA P15692 3/20 0.33
▸ HPSE Q9Y251 3/20 0.33
▸ PTPN2 P17706 1/20 0.33
▸ PTPN1 P18031 1/20 0.33
▸ ADRB2 P07550 1/20 0.33
▸ TACR1 P25103 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15505950 1.00 SSTR1 (0.52) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL13222916 1.00 SSTR1 (0.52) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL15871861 1.00 SSTR1 (0.52) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL13081507 1.00 SSTR1 (0.52) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL14605404 1.00 SSTR1 (0.52) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL2631946 1.00 SSTR1 (0.52) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL15003969 1.00 SSTR1 (0.52) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL13605427 0.98 SSTR1 (0.54) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL19356278 0.98 SSTR1 (0.54) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL15886871 0.98 SSTR1 (0.54) SSTR1SSTR2SSTR4SSTR3SSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2638053-B1 URACYL SPIROOXETANE NUCLEOSIDE PHOSPHORAMIDATES JANSSEN PRODUCTS LP (US) 2016-08-31 — — EP disclosed
WO-2015125782-A1 METHOD FOR PRODUCING THIOLANE-SKELETON GLYCOCONJUGATE, AND THIOLANE-SKELETON GLYCOCONJUGATE 富士フイルム株式会社 2015-08-27 — — WO disclosed
US-9012428-B2 Uracyl spirooxetane nucleoside phosphoramidates JANSSEN PRODUCTS, LP (US) 2015-04-21 — — US disclosed
US-9006209-B2 Uracyl spirooxetane nucleoside phosphoramidates JANSSEN PRODUCTS, LP (US) 2015-04-14 — — US disclosed
US-8933052-B2 Uracyl spirooxetane nucleosides JANSSEN PRODUCTS, LP (US) 2015-01-13 — — US disclosed
US-20130244968-A1 Uracyl Spirooxetane Nucleoside Phosphoramidates TIBOTEC BVBA (BE) 2013-09-19 — — US disclosed
US-20130225520-A1 Uracyl Spirooxetane Nucleoside Phosphoramidates TIBOTEC BVBA (BE) 2013-08-29 — — US disclosed
US-20130217648-A1 Uracyl Spirooxetane Nucleosides MEDIVIR AB (SE) 2013-08-22 — — US disclosed
US-8481510-B2 Uracyl spirooxetane nucleosides JANSSEN PRODUCTS, LP (US) 2013-07-09 — — US disclosed
US-8389565-B2 Antidiabetic agents; controlling carbohydrate metabolism SIMON FRASER UNIVERSITY (CA) 2013-03-05 — — US disclosed
US-20120065156-A1 Uracyl Spirooxetane Nucleosides TIBOTEC BVBA (BE) 2012-03-15 — — US disclosed
US-8133870-B2 Therapeutic furopyrimidines and thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2012-03-13 — — US disclosed
US-7939677-B2 Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation ISIS PHARMACEUTICALS, INC. (US) 2011-05-10 — — US disclosed
US-7875733-B2 Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing ISIS PHARMACEUTICALS, INC. (US) 2011-01-25 — — US disclosed
US-20110002886-A1 TETRAHYDROFURO [3,4-D] DIOXOLANE COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS AND CANCER BIOCRYST PHARMACEUTICALS, INC. (US) 2011-01-06 — — US disclosed
US-20100324277-A1 OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION ISIS PHARMACEUTICALS, INC. (US) 2010-12-23 — — US disclosed
WO-2010130726-A1 URACYL SPIROOXETANE NUCLEOSIDES CENTOCOR ORTHO BIOTECH PRODUCTS L.P. (US) 2010-11-18 — — WO disclosed
US-7514410-B2 Hepatitis C therapies BIOCRYST PHARMACEUTICALS, INC. (US) 2009-04-07 — — US disclosed
US-20080300200-A1 Therapeutic Furopyrimidines and Thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2008-12-04 — — US disclosed
WO-2007098597-A1 GLYCOSIDASE INHIBITORS AND METHODS OF SYNTHESIZING SAME SIMON FRASER UNIVERSITY (CA) 2007-09-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130244968-A1 Uracyl Spirooxetane Nucleoside Phosphoramidates NUDT1, UMPS, NUDT14 SSTR1 1721/4885SSTR2 2189/4885SSTR4 1048/4885
US-20080300200-A1 Therapeutic Furopyrimidines and Thienopyrimidines DPYD, TYMP, TYMS SSTR1 4452/4885SSTR2 4263/4885SSTR4 4099/4885
US-20130225520-A1 Uracyl Spirooxetane Nucleoside Phosphoramidates NUDT1, NUDT14, UMPS SSTR1 2931/4885SSTR2 3467/4885SSTR4 2145/4885
US-20120065156-A1 Uracyl Spirooxetane Nucleosides PNP, NUDT1, UMPS SSTR1 877/4885SSTR2 1981/4885SSTR4 1055/4885
US-20100324277-A1 OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION SNRPE, NSUN3, NSUN2 SSTR1 4849/4885SSTR2 4867/4885SSTR4 4844/4885
US-20130217648-A1 Uracyl Spirooxetane Nucleosides PNP, NUDT1, UMPS SSTR1 877/4885SSTR2 1981/4885SSTR4 1055/4885
US-20110002886-A1 TETRAHYDROFURO [3,4-D] DIOXOLANE COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS AND CANCER FDFT1, DHODH, DHPS SSTR1 3801/4885SSTR2 4639/4885SSTR4 3922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.